Practical Guide to the EMA’s Draft EU GMP Revisions

Is your organisation truly prepared for the EMA’s upcoming EU GMP revisions?

About this Whitepaper

A profound shift is taking place across the pharmaceutical and biotech sector as the EMA introduces major draft revisions to EU GMP. The updates to Chapter 4, Annex 11 and the brand‑new Annex 22 redefine expectations for documentation, computerised systems and the responsible use of AI in regulated environments. These changes mark a move towards fully digital, data‑driven quality systems where integrity, traceability and lifecycle governance take centre stage.

What’s changing?

Documentation now spans hybrid, electronic and multimedia formats, requiring stronger control, metadata management and secure retention processes.
Computerised systems face heightened expectations around validation, cybersecurity, supplier oversight and lifecycle governance.
Annex 22 introduces the first formal GMP framework for AI, demanding clear intended use, robust model validation and mandatory human oversight.
Data integrity principles (ALCOA++) now extend across all systems and formats, reinforcing the need for traceable, secure and reliable information.
Organisations must strengthen cross‑functional collaboration between Quality, IT, Manufacturing and Data Science to meet the new requirements.

Why it matters for your business

This updated regulatory landscape raises both the bar and the opportunity. Companies must:

Map and reassess documentation practices across all digital and hybrid records.
Ensure computerised systems remain compliant throughout their lifecycle, not just at validation.
Review cloud, SaaS and supplier relationships to align with stricter expectations.
Establish or reinforce AI governance frameworks before adoption accelerates.
Build audit readiness through transparent, well‑controlled data flows and cross‑functional accountability.

These revisions are tightly connected to quality management, data governance and digital maturity—impacting operational efficiency, inspection readiness and competitive positioning.

Take action now

With final publication expected in 2026, organisations should begin preparing immediately. Updating procedures, conducting gap assessments, enhancing validation strategies and strengthening AI oversight will be essential steps to ensure compliance and unlock the benefits of a modern, digital‑first quality system.

👉 Our full white paper provides clear guidance, practical recommendations and expert insights to help you navigate and implement the upcoming EMA GMP revisions with confidence.

Download the White Paper below

First Name

Last Name

Company

Job Title

Country

Marketing Opt In

Rephine respects your privacy. Choosing to check the box means that you agree to the Rephine Privacy Policy. You can unsubscribe at any time.

View our other resources and company news

Ensuring Compliance and Data Integrity in Pharmacovigilan

Case Study

GMP Audit Services

GxP Consultancy